This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baron, R. Articles by Rawadi, G. Search for Related Content PubMed PubMed Citation Articles by Baron, R. Articles by Rawadi, G. Pubmed/NCBI databases Substance via MeSH

Targeting the Wnt/ß-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton

Yale University School of Medicine (R.B.), New Haven, Connecticut 06520; and Galapagos (G.R.), 93230 Romainville, France

Address all correspondence and requests for reprints to: Dr. Roland Baron, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208044, New Haven, Connecticut 06520-8044. E-mail: roland.baron{at}yale.edu.

The recent identification of a link between bone mass in humans and gain- or loss-of-function mutations in the Wnt coreceptor low-density lipoprotein receptor-related protein 5 (osteoporosis pseudoglioma syndrome, high bone mass trait) or in the Wnt antagonist sclerostin (sclerosteosis, van Buchem syndrome) has called the attention of academic and industry scientists and clinicians to the importance of this signaling pathway in skeletal biology and disease. Multiple genetic and pharmacological manipulations of Wnt signaling in mice have since then confirmed the central role of this pathway in regulating bone formation.

This article has been cited by other articles:

				C. M. Edwards Wnt signaling: bone's defense against myeloma Blood, July 15, 2008; 112(2): 216 - 217. [Full Text] [PDF]

				Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma Blood, July 1, 2008; 112(1): 196 - 207. [Abstract] [Full Text] [PDF]

				P. Bovolenta, P. Esteve, J. M. Ruiz, E. Cisneros, and J. Lopez-Rios Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease J. Cell Sci., March 15, 2008; 121(6): 737 - 746. [Abstract] [Full Text] [PDF]

				P. t. Dijke, C. Krause, D. J. J. de Gorter, C. W.G.M. Lowik, and R. L. van Bezooijen Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 31 - 35. [Abstract] [Full Text] [PDF]

				T. J. Martin and K. W. Ng New Agents for the Treatment of Osteoporosis IBMS BoneKEy, November 1, 2007; 4(11): 287 - 298. [Abstract] [Full Text] [PDF]